Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in HFpEF
NCT06837623Phase 3Active, not recruiting
- Sponsor
- Cairo University
- Start
- Jul 2024
- Primary completion
- Feb 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of colchicine in heart failure with preserved ejection fraction (HFpEF), sponsored by Cairo University. Started Jul 2024; status: active, not recruiting.
02
Drugs
colchicine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06837623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837623.